Skip to main content
  • Print publication year: 2013
  • Online publication date: December 2013

Chapter 29 - The future: new concepts and potential therapies

from Section 7 - The Prognosis of Neuropathic Pain
Tricyclic antidepressants (TCAs) and serotonin norepinephrine reuptake inhibitors (SNRIs) (venlafaxine, duloxetine) are recommended as the first-line agents for peripheral neuropathic pain, especially for painful polyneuropathy, the other first-line options being gabapentinoids and topical lidocaine. Tricyclic antidepressants became a mainstay in the management of neuropathic pain before their mechanisms were elucidated and before the advent of systematic ways to evaluate their efficacy. Venlafaxine and duloxetine should be used with caution in patients with a history of mania, seizures, or bleeding tendency. Due to risk of excessive serotoninergic effect, they should be used with caution in patients receiving concomitant selective serotonin reuptake inhibitor (SSRI) or tramadol treatment. When selecting the treatment for an individual patient, comorbid conditions and their medications need to be taken into account. More detailed information of the effects of pharmacological agents on various symptoms of neuropathic pain and sensory profiles may guide drug selection in the future.
Recommend this book

Email your librarian or administrator to recommend adding this book to your organisation's collection.

Neuropathic Pain
  • Online ISBN: 9781139152211
  • Book DOI:
Please enter your name
Please enter a valid email address
Who would you like to send this to *


1. NightingaleS.The neuropathic pain market. Nat Rev Drug Discov 2012;11:101–2.
2. MilliganED, WatkinsLR.Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci 2009;10:23–36.
3. LaCroix-FralishML, AustinJS, ZhengFY, LevitinDJ, MogilJS.Patterns of pain: meta-analysis of microarray studies of pain. Pain 2011;152:1888–98.
4. GracePM, HurleyD, BarrattDT, et al. Harnessing pain heterogeneity and RNA transcriptome to identify blood-based pain biomarkers: a novel correlational study design and bioinformatics approach in a graded chronic constriction injury model. J Neurochem 2012;122:976–94.
5. ZeilhoferHU, WitschiR, HoslK.Subtype-selective GABAA receptor mimetics–novel antihyperalgesic agents?J Mol Med (Berl) 2009;87:465–9.
6. KnablJ, WitschiR, HoslK, et al. Reversal of pathological pain through specific spinal GABAA receptor subtypes. Nature 2008;451:330–4.
7. RudolphU, CrestaniF, BenkeD, et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature 1999;401:796–800.
8. LowK, CrestaniF, KeistR, et al. Molecular and neuronal substrate for the selective attenuation of anxiety. Science 2000;290:131–4.
9. ZeilhoferHU, MohlerH, Di LioA.GABAergic analgesia: new insights from mutant mice and subtype-selective agonists. Trends Pharmacol Sci 2009;30:397–402.
10. WangW, GuJ, LiYQ, TaoYX.Are voltage-gated sodium channels on the dorsal root ganglion involved in the development of neuropathic pain?Mol Pain 2011;7:16.
11. StricklandIT, MartindaleJC, WoodhamsPL, et al. Changes in the expression of NaV1.7, NaV1.8 and NaV1.9 in a distinct population of dorsal root ganglia innervating the rat knee joint in a model of chronic inflammatory joint pain. Eur J Pain 2008;12:564–72.
12. AkopianAN, SouslovaV, EnglandS, et al. The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nat Neurosci 1999;2:541–8.
13. SnutchTP.Targeting chronic and neuropathic pain: the N-type calcium channel comes of age. NeuroRx 2005;2:662–70.
14. ChizhBA, GreenspanJD, CaseyKL, NemenovMI, TreedeRD.Identifying biological markers of activity in human nociceptive pathways to facilitate analgesic drug development. Pain 2008;140:249–53.
15. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69(3):89–95.
16. WagnerJA.Biomarkers: principles, policies, and practice. Clin Pharmacol Ther 2009;86:3–7.
17. EdwardsRR.Genetic predictors of acute and chronic pain. Curr Rheumatol Rep 2006;8:411–17.
18. AngDC, MooreMN, HilligossJ, TabbeyR.MCP-1 and IL-8 as pain biomarkers in fibromyalgia: a pilot study. Pain Med 2011;12:1154–61.
19. DesireddiNV, CampbellPL, SternJA, et al. Monocyte chemoattractant protein-1 and macrophage inflammatory protein-1alpha as possible biomarkers for the chronic pelvic pain syndrome. J Urol 2008;179:1857–61; discussion 61–2.
20. BoldtI, Eriks-HooglandI, BrinkhofMW, BieRA, von ElmE.Non-pharmacological interventions for chronic pain in people with spinal cord injury. Cochrane Database Syst Rev 2011;7:CD009177.
21. ParkJ, HughesAK.Nonpharmacological approaches to the management of chronic pain in community-dwelling older adults: a review of empirical evidence. J Am Geriatr Soc 2012;60:555–68.
22. O’ConnellNE, WandBM, MarstonL, SpencerS, DeSouzaLH.Non-invasive brain stimulation techniques for chronic pain. Cochrane Database Syst Rev 2010;9:CD008208.
23. Mailis-GagnonAF, SandovalJA, TaylorRS. Spinal cord stimulation for chronic pain. Cochrane Database Syst Rev 2004;3.
24. LamontK, ChinM, KoganM.Mirror box therapy: seeing is believing. Explore (NY) 2011;7:369–72.
25. BenedettiF.Mechanisms of placebo and placebo-related effects across diseases and treatments. Annu Rev Pharmacol Toxicol 2008;48:33–60.
26. KaptchukTJ, KelleyJM, ConboyLA, et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. Br Med J 2008;336:999–1003.
27. JamshidianF, HubbardAE, JewellNP. Accounting for perception, placebo and unmasking effects in estimating treatment effects in randomised clinical trials. Stat Methods Med Res. 2011 Sep 8. [Epub ahead of print]
28. BingelU, WanigasekeraV, WiechK, et al. The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil. Sci Transl Med 2011;3:70ra14.
29. FinnissDG, KaptchukTJ, MillerF, BenedettiF.Biological, clinical, and ethical advances of placebo effects. Lancet 2010;375:686–95.